Compare CULP & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CULP | XLO |
|---|---|---|
| Founded | 1972 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Textiles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.8M | 39.4M |
| IPO Year | 1994 | 2021 |
| Metric | CULP | XLO |
|---|---|---|
| Price | $2.77 | $8.45 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | 32.6K | ★ 264.1K |
| Earning Date | 03-11-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $213,237,000.00 | $43,766,000.00 |
| Revenue This Year | N/A | $88.66 |
| Revenue Next Year | $8.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 589.88 |
| 52 Week Low | $2.70 | $0.46 |
| 52 Week High | $5.20 | $9.25 |
| Indicator | CULP | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 31.67 | 88.35 |
| Support Level | $2.73 | $0.63 |
| Resistance Level | $3.60 | N/A |
| Average True Range (ATR) | 0.20 | 0.49 |
| MACD | -0.00 | 0.45 |
| Stochastic Oscillator | 16.22 | 90.50 |
Culp Inc manufactures, markets mattress fabrics for bedding and upholstery fabrics for residential, commercial, and hospitality furnishings. The company has two operating segments: Mattress fabrics, which generate maximum revenue, and Upholstery fabrics. The mattress fabrics segment manufactures, sources, and sells fabrics and mattress covers to bedding manufacturers. The upholstery fabrics segment develops, sources, manufactures, and sells fabrics to residential, commercial, and hospitality furniture manufacturers. Geographically, it derives key revenue from the United States of America.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.